GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment
(WorldNews France)

GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients Three Years After LUMEVOQ® Treatment 06 Jul 2020 07:30 CEST Company Name GENSIGHT BIOLOGICS ISN FR0013183985 Market Euronext Symbol SIGHT Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported that Leber Hereditary Optical Neuropathy (LHON) subjects treated with LUMEVOQ® experienced sustained efficacy and safety three years after a single injection with the gene therapy. These findings come...